BioPharmaStock
HomeAsk About StockNewsIdeasHistoryFDA DesignationsElite Program

BLCO

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

  • Bausch + Lomb advanced two potential first-in-class eye health therapies based on clinical trial resultsAug 25, 2026
  • Bausch + Lomb received FDA 510(k) clearance for its dual-port vitrectomy cutter and fluidics updateApr 8, 2026
  • Bausch + Lomb reported positive 24-month U.S. data for the ELIOS system in glaucoma treatmentMar 23, 2026
  • Bausch + Lomb announces publication of Phase 3 data on LUMIFY® preservative-free redness reliever eye dropsJul 29, 2025
  • Bausch + Lomb launches new LUMIFY® preservative-free redness reliever eye drops in the U.S.May 21, 2025

    Bio Pharma Stock

    Where Science Meets Investing.

    BioPharmaStock is a specialized biopharmaceutical investment intelligence company focused exclusively on publicly traded biotechnology and pharmaceutical companies. Our research team continuously analyzes clinical trials, FDA regulatory events, scientific publications, corporate developments, and market catalysts to deliver timely research and exclusive insights for investors seeking opportunities in one of the world's most knowledge-intensive sectors.

    ALNJAM ALAALI SOFTWARE DESIGN CO. L.L.C, UAE, Abu Dhabi

    BioPharmaStock LogoBioPharmaStock Logo

    Quick Links

    • Home
    • Ask About Stock
    • News
    • Ideas
    • History
    • FDA Designations
    • Elite Program

    Contact Us

    Email: info@biopharmastock.com

    Phone: +971 50 936 3328

    Join Our Community→

    Follow Us

    Get the App

    Instant notifications on your phone

    Download on theApp StoreGet it onGoogle Play

    © 2026 Bio Pharma Stock. All rights reserved. Policy